title: Biosimilars and the long game.
abstract: Despite greater certainty for biosimilar markets and regulation, the change that was seen in the small-molecule pharmaceuticals market with the rapid entrance of emerging-country generics suppliers will not be replicated exactly. The long game has yet to be played out, and recent changes in regulation, science, and production technology are likely to impact on future patterns of partnership and production.
authors.affiliation: Science Technology and Innovation Studies, School of Social and Political Sciences, University of Edinburgh, Old Surgeons Hall, High School Yards, Edinburgh EH1 1LZ, UK. Electronic address: farah.huzair@ed.ac.uk.
authors.forename: Farah
authors.initials: F
authors.lastname: Huzair
authors.affiliation: The Open University, Development Policy and Practice, Faculty of Maths, Computing, and Technology, The Open University, Walton Hall, Milton Keynes MK7 6AA, UK.
authors.forename: Dinar
authors.initials: D
authors.lastname: Kale
mesh_terms: D059451:Biosimilar Pharmaceuticals; D015195:Drug Design; D004345:Drug Industry / Q000639:trends*; D004335:Drug and Narcotic Control / Q000639:trends*
chemical_list: D059451:Biosimilar Pharmaceuticals
keywords: biosimilar; follow-on biologic; subsequent entry biologic